KR100378745B1 - Compound preparations of Chinese traditional medicine for diabetes - Google Patents

Abstract

The present invention relates to herbal medicines for the treatment of diabetes mellitus and a preparation method thereof, the herbal medicines for the preparation of herbal medicines are extracted from sulfur, ginseng, gimo, Dansam as active ingredients. It is used to treat diabetes, especially type II diabetes, and has therapeutic effects such as lowering blood sugar, urine glucose, or gradually restoring the function of the spleen (pancreatic islet). After over 6000 clinical treatments for diabetics, the total efficacy of the formulation was found to be 96.33%.

Description

Compound preparations of Chinese traditional medicine for diabetes}

The present invention relates to an antidiabetic agent, and more particularly, to an herbal remedies for treating diabetes based on herbal medicines and a preparation method thereof.

Diabetes is called thirst in oriental medicine, and there are already more than 2000 years of history in China. Diabetes mellitus is a chronic disease, a complex disease caused by the metabolic disturbances of sugars, fats and proteins caused by the relative or absolute lack of insulin in the body. Diabetes has a high incidence and long duration of treatment, and is now referred to as three major diseases, along with cancer and angiocardiopathy and cerebrovascular disease. The incidence of diabetes is gradually increasing due to the improvement of modern living standards, the improvement of the food structure, the change of lifestyle and the genetic factors. Rough statistics show that there are currently about 30 million people with diabetes in China, an increase of about 700,000 every year. Diabetes is divided into two types, type I and type II. Type I is insulin-dependent and type II is non-insulin dependent. Among them, type II patients, namely non-insulin-dependent diabetes patients, account for about 90% of the total number of patients, greatly threatening the health and life of people. However, conventionally at home and abroad has not been developed the ideal drug for the fundamental treatment of diabetes.

In both cases, in order to treat diabetes, drugs such as sulfonylureas, thyldiguaniadum, and insulin are used. These drugs have a definite effect on lowering blood sugar levels, but they are only enough to treat metabolic disturbances. In addition, the long-term side effects are severe and damage to the liver and kidneys and affect the gastrointestinal function, which will lead to more difficult prevention and treatment of the complications.

Although there is a long history of diabetes treatment in oriental medicine, conventional herbal medicines only play a role in lowering blood sugar, resulting in a temporary treatment effect, but not a fundamental therapeutic effect.

Accordingly, an object of the present invention is to provide a diabetic therapeutic agent and a method for preparing the same, which can temporarily lower blood sugar and urine glucose, as well as restore insulin function by fundamentally treating diabetes.

In order to achieve the above object, the diabetic therapeutic agent according to the present invention is based on the current Chinese medical opinions and treatment principles on the causes of the development of diabetes mellitus and its complications, and with reference to the results of modern pharmacological research, ), Bobby Ixin ( ), Pterosaur ( ), Whole heartbeat ( Select a Chinese medicine, combine the medicine according to the theory of Chinese medicine, and take the essence of it. ), Non-new permit ( ), Rockmac Stir ( ), Volume control ( To treat diabetes, especially Type II diabetes

In more detail, the anti-diabetic agent according to the present invention provides a kind of herbal remedies, wherein the preparation is composed of an active ingredient obtained by adding alcohol and / or water to the following raw materials or the following raw materials. .

goldthread( 600-900 ginseng powder ) 450-750 weight

Astragalus 800-1200 weight portion Hyunsam ( ) 450-550 weight

Jimo 550-750 wt. 780-1420 weight

Creation( 450-550 wt. 550-750 weight

Hojang 450-550 weight parts phalanges 550-750 weight

Raw material blending weight ratio (preferred in the above-mentioned herbal medicine) ) Is as follows.

Sulfur 700-780 wt% Ginseng 570-630 wt%

Astragalus 970-1070 Weighted Hyunsam 475-525 Weighted

630-700 weight parts Yellowish white 1100-1250 weight parts

Creation 475-525 Weight Ingredient Salvia 630-700 Weight

Hojang 475-525 Weight Weight Phalanx 630-700 Weight

The herbal medicines described above are powdered, filled (powdered), capsules, unified ( Can be prepared in any pharmaceutical form within the scope of pharmacy, such as oral solution or pill. Preparation of the herbal medicine preparation of the present invention may also proceed according to the preparation method of the general herbal medicine.

It is particularly preferable to prepare the herbal medicines according to the present invention according to the following method.

The process of preparing the herbal medicines herbal medicines of the present invention with the above-described herbal medicines is as follows.

(1) Raw materials are prepared by measuring the following amount of herbal medicine with the balance:

Sulfur 600-900 wt% Ginseng 450-750 wt%

Astragalus 800-1200 weight part Hyunsam 450-550 weight part

Jimo 550-750 Weight Weight Yellow White 780-1420 Weight Weight

Creation 450-550 weight part Salvia hemp 550-750 weight part

Soy sauce 450-550 parts by weight Phalanges 550-750 parts by weight.

(2) After adding alcohol and / or water to the powder powder of ginseng described above, and heating heating ( The extract obtained by the above step is regarded as the active ingredient I.

(3) The leaching solution obtained by adding water or acidic water to the powder of sulfur and sulfur white mentioned above is used as active ingredient II.

(4) After dipping the other seven herbs described above in water, the extract obtained by heating is used as active ingredient III.

(5) The diabetes-protective agent according to the present invention is obtained by mixing the above-mentioned active ingredients I, II and III evenly.

Ginseng has an excellent effect on rejuvenation and helping the spleen and lungs. The active ingredient of ginseng is ginsenoside. It is preferable to perform the heating spin described in step (2) three times. As the heating spin liquid, an aqueous ethyl alcohol solution is preferably used. More preferably, an aqueous 55% -80% aqueous ethyl alcohol solution is most preferred. Preferably, 75% ethyl alcohol aqueous solution is used. If the ethyl alcohol concentration is too high or too low, the yield of ginsenosides is reduced.

The extraction with water in step (4) is carried out three times, and each time for 2 hours, the amount of solvent (the amount of solvent for dissolving the solute) is preferably 10 times the mass of the solvent.

Hereinafter, the present invention will be described in detail through examples of herbal remedies according to the present invention, animal experiments, and clinical examples of diabetes treatment.

Example 1 Preparation of Herbal Medicine Capsule a

(1) Prepare each raw material according to the following weight ratio.

Sulfur 740 wt. Ginseng 600 wt.

Astragalus 1020 wt% Hyunsam 500 wt%

666 weight parts yellow white 1200 weight parts

500 kg by weight, Salvia 666 weight

Hojang 500 weight powder Phalanges 666 weight powder

(2) Prepare ginseng powder according to the above-mentioned blending ratio, add 75% ethyl alcohol solution and heat three times. The first time is added 4 times of 75% concentration of ethyl alcohol solution and heated for 4 hours, the second time is added 2 times of 75% concentration of ethyl alcohol solution and heated for 2 hours; The third time, 2 times the 75% concentration of ethyl alcohol solution was added and heated for 2 hours. The extract obtained by heating three times is mixed, ethyl alcohol used as a solvent is separated, and water is separated four times with a normal propyl alcohol saturated solution (water: normal propyl alcohol = 1: 2). Leave on for 10 hours each time, add normal propyl alcohol solution and separate normal propyl alcohol. Next, it is dried at 80 ° C and used to make a fine powder.

(3) In accordance with the above-described blending ratio, rhubarb and yellow-white powdered powder is taken out and cooled three times in 0.2% sulfuric acid aqueous solution. The first time is stirred with 24 times of 0.2% sulfuric acid solution and stirred for 24 hours, and the second time is stirred with 24 times of 0.2% sulfuric acid solution and stirred for 24 hours. The third time, three times of 0.2% sulfuric acid solution was added and stirred to cool for 24 hours. Next, three extracts were mixed and filtered to reach pH 9-11. ) And filter again and add 10% sodium chloride (w / v) solution and stir. Next, adjust to pH2-3 with hydrochloric acid and leave for one day. Subsequently, the precipitate obtained by filtration of the solution is washed with a small amount of water, dried and dried at a temperature of 80 ° C. to produce fine powder.

(4) Take the remaining seven herbs in accordance with the above-mentioned combination ratio to remove impurities, and wash the dirt and dust thoroughly with water. Next, add 10 times the amount of herbal medicine, soak for 2 hours, and heat. Calculate the water boiling time, the first heating for 2 hours, the second pour 6 times of water to heat for 1.5 hours, the third to 5 times to pour water for 1.5 hours. After tertiary extraction was mixed and left overnight, the clear solution was taken and ethyl alcohol was added to precipitate ethyl alcohol in the usual manner. At this time, the pressure is reduced in a vacuum state so that the relative density is 1.1. Next, 95% ethyl alcohol solution was added, and the solution was adjusted to 70% ethyl alcohol content. Ethyl alcohol solution is added, stirred vigorously for 2 hours, and left overnight (about 24 hours). Take the clear solution above to separate ethyl alcohol, concentrate to 1.15 specific gravity and spray dry.

(5) The above-mentioned three dried powders are mixed evenly, 88% of ethyl alcohol aqueous solution is added, and mixed evenly with a mixer. Next oscillating granulator ) Into a No. 14 tablet, dried with a 60 ° C. constant temperature hot air blower to make the amount of water less than 9%, and then take No. 16 pills into a No. 0 capsule to obtain a capsule of the present invention having a mass of 0.4 g. One gram of powder is equivalent to approximately 19 grams of herbal medicine.

Example 2 Preparation of Herbal Medicine Capsule ｂ

(1) prepare each composition medicine according to the following formulation ratio;

Sulfur 900 weights ginseng 750 weights

Astragalus 1200 weight part Hyunsam 550 weight part

Jimo 750 wt% Yellowish white 1420 wt%

Creation of 550 wt.

Soy sauce 550 wt.

(2) Prepare ginseng powder according to the above-mentioned weight ratio, add 55% aqueous ethyl alcohol solution and heat. The first time is heated for 3 hours after adding 4 times of 55% ethyl alcohol, the second time is heated for 3 hours after adding 2 times 55% ethyl alcohol, and the third time is 2 times Add 55% ethyl alcohol and heat for 3 hours. The next three samples are mixed and ethyl alcohol is separated. Water is separated four times with a saturated aqueous solution of propyl alcohol (water: propyl alcohol = 1: 2). Leave for 10 hours each time, add propyl alcohol solution, and separate propyl alcohol. Next, after drying at 80 degreeC, a particle becomes fine powder.

(3) In accordance with the above-mentioned weight ratio, sulfur and powdered white powder are taken and cooled three times in water. The first time is added to 5 times of water and stirred and cooled for 48 hours, the second time is added to 4 times of water and stirred to cool for 48 hours, and the third time is added to 3 times of water and stirred for 48 hours. Allow to cool. Next, three extracts were mixed and filtered, and then a 10% sodium chloride (w / v) solution was added and stirred. Subsequently, it was adjusted to pH 2-3 with aqueous sulfuric acid solution and left overnight, and then filtered. The precipitate was washed with a small amount of water, drained, and dried at 80 ° C. to obtain fine powder.

(4) Take the remaining seven herbs in accordance with the above weight ratio, remove impurities and wash the dirt and dust thoroughly with water. Next, add 8 times the amount of herbal medicine, soak for 2 hours, and heat.

The first time is heated for 2 hours, the second time is heated for 1.5 hours with 6 times the amount of water, and the third time is heated for 2 hours with 5 times of water. After mixing three times the solution and left overnight, the clear solution is extracted, put ethyl alcohol, concentrated by alcohol precipitation according to the general method, and then spray-dried.

(5) After mixing the above-mentioned three dry powder evenly, make a pill according to the procedure (5) of Example 1 and dry it, and put it in the capsule No. 0. The tablet is 0.4g of pill each, which is the capsule of the present invention. One gram of powdered powder corresponds to approximately 19 grams of herbal medicine.

Example 3: Preparation of herbal medicine capsule c

(1) prepare each herbal medicine in accordance with the following weight ratio;

600 parts by weight of brown lotus 450 parts by weight of ginseng

Astragalus 800 weight powder Hyunsam 450 weight powder

Jimo 550 wt% Yellow and white 780 wt%

Creation 450 wt. Weight Salvia 550 wt.

Soy sauce 450 wt.

(2) Prepare ginseng powder according to the above-mentioned weight ratio, add water 10 times the weight of herbal medicine, soak for 2 hours, and heat. The first time is heated for 16 hours, the second time is added 6 times of water and heated for 12 hours, and the third time is added 5 times of water and heated for 8 hours. Next, three extracts were mixed and purified four times with a saturated aqueous solution of normal propyl alcohol (water: normal propyl alcohol = 1: 2). 10 hours of politics each time ( After mixing, normal propyl alcohol is separated and dried and dried at 80 ℃ to make fine powder.

(3) According to the above-mentioned weight ratio, take sulfur powder and sulfur white powder powder, cool it three times in 0.3% hydrochloric acid solution, and adjust to 2 mol / L sodium hydroxide to pH9-11. Other procedures are the same as those of Example (3). The precipitate obtained is dried and then made into fine powder.

(4) Take the remaining seven herbs according to the above weight ratio, remove impurities, wash the dirt and dust with water, add 8 times the amount of herbal medicine, soak for 2 hours and heat. Calculate the water boiling time, the first time is heated for 2 hours, the second time is added 6 times of water and heated for 1.5 hours, the third time is added 5 times of water and heated for 1.5 hours. After mixing three times the collected solution and left overnight, the above clear solution is extracted, ethyl alcohol is added, alcoholic precipitate is concentrated according to the general method, and then spray-dried.

(5) After mixing the above-mentioned three dry powder evenly, after making the kernel according to the process (5) of Example 1 and dried, put into 0 capsules. The tablet is 0.4 g of pill each, which is the capsule c of the present invention. One gram of powdered powder corresponds to approximately 19 grams of herbal medicine.

Example 4 Preparation of Herbal Medicine Abdominal Filler (Urim Forest Drug) a

Prepare each composition part according to the method described in Example 1 according to the following weight mix ratio.

Sulfur 900 weights ginseng 750 weights

Astragalus 1200 weight part Hyunsam 550 weight part

Jimo 750 wt% Yellowish white 1420 wt%

Creation of 550 wt.

Hojang 500 parts by weight Jigolpi 750 parts by weight

When the obtained powdered powder is mixed and dried, 430 g of Chinese herbal medicines can be obtained.

Example 5 Preparation of Chinese Medicine Abdominal Filler

According to the method of Example 1, according to the following compounding ratio to prepare each composition part.

Sulfur 600 wt% Ginseng 650 wt%

Astragalus 800 weight powder Hyunsam 450 weight powder

Jimo 550 wt% Yellow and white 780 wt%

Creation 450 wt. Weight Salvia 550 wt.

Soy sauce 450 wt.

When the obtained powdered powder is mixed and dried, about 380 g of herbal filling b is obtained.

Example 6: Preparation of herbal medicine pills

According to the method described in Example 1, but according to the general method for the preparation of herbal pills. Each pill contains about 1.2g of medicinal powder and 1g of medicinal powder is approximately 19g of herbal medicine.

Example 7: Preparation of herbal medicines

According to the method described in Example 1, the preparation is made according to the preparation method of the general herbal medicine preparation. Each preparation contains about 0.3g of medicinal powder, and 1g of medicinal powder is approximately 19g of herbal medicine.

Experimental Example 1 Animal Acute Toxicity Test by Capsule

The capsule a is used to calculate the LD ₅₀ by one observation of the toxic response and death of the animal. Capsule (a powder) is diluted with distilled water according to the required concentration during the experiment.

Experimental animals were 50 rats of ICR breed, with male and female each half weighing 18-22 g. They are provided by the Laboratory Animal Center of Xi'an Medical University. 08-005. Laboratory room temperature is 18-20 ° C., relative humidity 60% -70%, ventilated with ventilator, natural light source 12 hours / day. Depending on your gender, you can keep 10 mocks in each mock and clean the mock every 3 days.

After preliminary experiment, decide to give medicine according to the following method. The capsule a medicinal powder is diluted with distilled water to make suspensions of different concentrations, the order of concentration being 46.87%, 37.5%, 30.0%, 24.0%, and 19.2%, respectively. 50 rats of ICR type are selected and randomly divided into 5 groups, and each group has half males. After 14 hours of fasting, 0.2 ml / 10 g of the above suspension of different concentrations of Inject). Seven days after the infusion, the general situation and the death situation of each group were observed. After infusion, the young rats had less activity, their hair was straightened, their body curled, their breathing was tight, and their mucous membranes were dark red. Death occurred within 4-48 hours after drug injection. At death, the mucous membranes were vividly reddish and there were no special symptoms such as swelling of eyes, discharge of secretions or severe cramps. The dead bodies of the rats were examined one by one and found several spots of bleeding scattered in the gastric pyloric region.The main internal organs were dark in color, but the heart, liver, spleen, lungs, kidneys, adrenal glands, thymus, intestines and abdominal cavity No abnormalities in form were found in major internal organs. The results are shown in the table below (LD ₅₀ calculation was done with NDST software).

TABLE 1

Half deaths due to capsule a ( LD ₅₀ (Bliss method)

Striking index: G = 0.2406 X50 = 0.7886 Sx = 0.0304; G is relatively small and omitted.

Heterogeneity index: Chi2 = 0.16 Chi2.05 = 7.82 Sb = 1.6831; No heterogeneity.

Regression Equation: Y (Probit) = -0.3040 + 6.7256 * log (D)

r = 0.9951

LD ₅₀ = 6.1466 +/- 1.2024 (5.0607-7.4656)

Feiller heterogeneity correction: Sx = 0.0080 Sb = 0.3850

LD ₅₀ = 6.1466 +/- 0.2911 (5.8624-6.4446)

As can be seen, the LD ₅₀ of capsule a given to the rats of the ICR breed is 6.1466 g / kg (65.15 / kg, which is calculated by herbal medicine), and the confidence limit of LD ₅₀ is 5.8624-6.4466. It is limited to g / kg (corresponding to 62.14-68.31 / kg calculated as herbal).

Animal Experimental Example 2: Long-term toxicity test of capsule a (6 months long-term toxicity test in large rats)

Long-term experiments were conducted on the toxic reactions caused by capsule a by injecting medicines into large rats for 6 consecutive months. The first symptoms observed, the extent of symptoms, and toxic reactions ( In order to determine the amount of non-toxic reaction drug according to the target organ of the organization and the recovery and development situation of the organ, it is provided as a reference in determining the safe amount for the human body.

Capsule (a powder) is diluted with distilled water according to the required concentration.

Large rats of the SD series of test animals were provided by the Experimental Animal Center of Xi'an Medical University. Animals weigh between 96 and 104 g, with half each male.

160 large healthy rats were selected and divided into 4 groups, 40 in each group, and half of each male. Different concentrations of drugs were injected into the tanks, and the amount is as follows.

Unadministered base bath: 20 ml / kg (corresponding to 20 ml per kg of body weight) of distilled water was injected above.

Large dose tank of Capsule a: 20 ml / kg of Capsule a powdered suspension of 17.5% concentration was injected. That is, 3.5 g / kg (medicine content), which is roughly 50 times the daily dose of clinical patients (adult dose: 3 / day × 4 tablets / time × 0.41 g / pill ÷ 70 kg = 0.07 g / kg ).

Weight Dosing Tank: 8.075% of the suspension is infused on a 20 ml / kg basis. That is, 1.75 g / kg (weak dose), which corresponds to approximately 25 times the daily dose of clinical patients.

Small Dosing Vessel: Infusion of 1.75% of the suspension on a 20 ml / kg basis. Ie 0.35 g / kg (weak dose), which is approximately five times the daily dose of clinical patients.

Animal test conditions: The air temperature is controlled to 18-24 ° C, the relative humidity is 45% -70% with an air conditioner, the air is ventilated with a ventilator, and exposed to natural light at 12 hours / day. The laboratory animal center of Xi'an Medical University feeds on solid foods prepared according to the standard formulation and freely tap water. Depending on your gender, you can raise 5 mocks and mock them every 3 days. Adaptation The drug is administered once daily from a week later, the same as the route of administration in the clinic. According to three months of clinical treatment, the long-term poisoning cycle in large rats is six months. Three months after the administration of the drug, each group kills half (20), and six months after the administration of the drug, the remaining two-thirds of the animals (14) are killed and tested. Do a recovery session after about one week of suspension. Medication is given every day for 6 days, 8-9 am daily.

Inspection items:

1. Changes in general condition and weight: Observe the mental state, activity, secretions, food, feces, hair, and skin of each group in large order. Measure your weight once every two weeks and adjust the amount of medication as your weight changes. After administering the medicine, prepare metabolic mocking of large rats in the recovery period after 3 months, 6 months and drug suspension, and divide the animals in parallel to measure the 24-hour food intake (g / 100g body weight) of the large rats. The number of metabolic mocks is limited, so randomly check 10 dogs each time for 2 groups.

2. Hematology test: Injecting the drug into the stomach for 3 months, 6 months, and after the drug stops, the blood is collected from the bone artery. Check).

3. Blood biochemical test: Inject the medicine into the stomach, and after 3 months, 6 months, and after the suspension, the blood is drawn from the bone artery and examined for general biochemistry of each animal. These include Analineaminotransferase (ALT), Aspartic Acid Transcase (AST), Alkaline Phosphate (ALP), Total Protein (TP), White Protein (ALB), Urea Nitrogen (BUN), and Creatinine (Crea) Total bilirubin (T-BIL), blood sugar (GLu) and the like.

4. urine fluid Inspection: The inspection time is as described above. The urine fluid was collected from the metabolic mockery of large rats, and the color, urine flushing, urine glucose, and urine ketone ( ), Urine protein, red blood cells, white blood cells, etc. are examined.

5. Electrocardiogram: Test time is as above. Primarily a standard II guided electrocardiogram is examined.

6. System anatomy: Inspection time is as above.

7. Major internal organ counts: Test time is as above. The test items are nine internal organs such as heart, liver, spleen, lung, kidney, adrenal gland, testes and ovaries.

8. Histopathology: The test time is as above. Test items include heart, liver, spleen, lung, kidney, stomach and head, duodenum and jejunum ( ), Colon, bladder, and intestinal membrane ), Testicles, epididymis, ovaries, uterus, sternum (bone marrow), cerebrum, pituitary gland, adrenal gland, thymus, thyroid gland and 21 tissues.

The general condition of the large rats was good and the hair was shiny and the mental state and activity were normal. There was no secretion in eyes and nose, and no athlete's foot or ulcer on skin. 24 hours food intake was normal and there was no statistical significance in comparison with baseline (P> 0.05). This suggests that capsule a is injected into the stomach for 3 and 6 months and does not have a significant effect on changes in general condition and weight of large rats. The above results are shown in Tables 2 and 3 below.

TABLE 2

Effect of Capsule A on 24 Hour Food Intake in Large Rats

TABLE 3

Effect of Capsule a on Weight Change in Large Rats

3 months, 6 months after recovery and pentobarbital sodium ip ( After anesthesia with light anesthesia, blood was collected from the bone artery Normal inspection was carried out. As a result, there were no significant changes in blood levels of the animals injected with drugs, and they were all in the normal physiological range, and there was no significant difference compared to the reference groups (P> 0.05). This suggests that the drug does not have a pronounced abnormal effect in the blood of large rats. The results are shown in Table 4.

Three months, six months after the injection of the drug and pentobarbital sodium ip after anesthesia, light anesthesia was performed, and blood was collected from the bone artery. Function, blood sugar, and the like. As a result, after injecting the drug for 3 months or 6 months, the blood glucose of the high-dose tank decreased significantly, compared with the reference tank (P <0.01). The biochemical test values of other items were normal and there was no statistical significance (P> 0.05). This indicates that the drug does not have a significant abnormal effect on the gene transferase, liver function, renal function of the large rats, the results are shown in Table 5.

Urinary fluid was collected by metabolic mocking of large rats for 3 months, 6 months, and recovery after drug suspension, and 10 urine samples were collected in each group, and urine fluid normalization was performed on 6 recovering animals. As a result, urine fluid normal of each animal was normal and urine glucose, urine ketone, urine protein, and urinalysis test were all negative. Red blood cells and white blood cells were not found under the microscope, indicating that the drug had no adverse effects on urine fluid regulation in large rats. The results are shown in Table 6.

Injecting the drug into the limbs under light anesthesia with pentobarbital sodium ip after 3 months, 6 months and recovery period, and measuring standard II-induced electrocardiography, the large rats injected with the drug had normal heart rate and heart rate. Even in the ST stage, T wave and other angular waves, no abnormality was found. Compared to the reference group, the ECG did not change abnormally, indicating that capsule a had no adverse effect on the ECG of large rats.

Table 4

Effect of Capsule a on Blood Rats at 3, 6, and 14 days after drug infusion

Table 5

Effect of Capsule a on Blood Biochemical Indicators in Large Rats 3, 6, and 14 Days After Drug Infusion

* P <0.05, ** P <0.01 compared to baseline

[Table 6] Effect of capsule a on urinary fluid regulation in large rats

Table 7

Effect of Capsule a on Visceral Factors in Large Rats 3, 6, and 14 Days After Infusion

Three, six and six months after the infusion, blood was drawn from the bone artery, and 20, 14, and 6 large rats were killed, and the bodies were examined in turn. Colors of major internal organs and body cavities such as the heart, liver, lungs, spleen, kidneys, stomach, jejunum, colon, bladder, gallbladder, adrenal gland, thymus, testes, ovaries, uterus, brain, pituitary gland, abdominal cavity, thoracic cavity, etc. , Shape, military ) And the like. As a result, there were no abnormalities in the color and shape of the main organs and body cavity of each animal, and no pathological changes were observed by the naked eye.

Three months, six months after the injection, and immediately after the animals were killed and visually examined, each animal's heart, liver, spleen, lung, kidney, adrenal gland, thymus, testes, and ovaries were taken out and absorbed by filter paper and then internal organs. Depending on the size of the ) After measuring ) (g / 100g body weight or mg / 100g body weight) was obtained. As a result, each visceral coefficient was within the normal physiological range and there was no statistical significance in comparison with the reference group (P> 0/05). This suggests that the drug does not adversely affect visceral organ counts in large rats (results are shown in Table 7).

Bleed artery of each animal after 3 months, 6 months after recovery and 20, 14, and 6 mice were killed and the internal organs were taken out for histopathological examination. Among them, the intestines were taken out of all the reference tanks and the large dose tanks, and six viscera were taken out of the weight and small dose tanks, respectively. Visceral tissue includes the heart, liver, spleen, kidneys, stomach, duodenum, jejunum, colon, intestinal membranes, adrenal glands, thymus, thyroid gland, testes, epididymis, ovaries, uterus, sternum (bone marrow), brain, and pituitary gland. Considering this drug lowers blood sugar and increases the histopathology of spleen, all 21 tissues were included. Fix with 10% formalin solution and embed paraffin ( HE staining under) was compared with the reference bath under normal optical microscope. As a result, the tissues of each group of animals fed the drug had clear tissue nodules and the redness, species, degeneration Pathological changes such as necrosis and cell infiltration were not found, suggesting that capsule a does not cause toxic and delayed pathological changes.

In the long-term toxicity test in which capsule A powder was injected into large rats for 6 months, no obvious toxic and delayed toxic reactions occurred. The dose of non-toxic drug according to the body weight of the animal was 3.5 g / kg · day, which was approximately 50 times the dose of the clinical patient.

After injecting the above medicine, the general situation of the animals was observed every day, and the body weight was measured once every two weeks, and the amount of medicine was adjusted according to the weight.

Three months after the injection of the drug, half of the animals were killed and six months after the injection of the drug, two thirds of the remaining animals were killed, and the remaining one third of the animals were used in the recovery phase experiment two weeks after the drug was stopped. . Experimental results showed that capsule a had no significant effect on the general condition, hematology, blood biochemistry, urine fluid and electrocardiogram of animals in 3 months, 6 months and recovery period. Did not find. From the above experiments, no significant or delayed toxic responses were found in the long-term toxicity test of large rats injected with the drug for 6 months.

Animal Experimental Example 3: Major Pharmacologic Effects of Capsule a Related to Major Treatment of Function ( ) Experiment.

Normal mouse, alloxane Auditor of capsule a in hyperglycemic large rats of type (adrenergic type) and adrenaline type ) Action and the equivalent of the rabbit Experiments on the effects of) will provide a basis for accurately evaluating the pharmacological action of the drug.

Capsule A is used as the experimental drug and distilled water is used as the solvent. A suspension of the required concentration was prepared with distilled water. Experimental animals were young rats of ICR breed, large rats of SD breed, and Japanese big-eared rabbit. All were provided by Xi'an Medical University Laboratory Animal Center, and the certificate number is 08-005. The body weight of the young rats ranged from 22-25g, 180-250g for the large rats, and 2.0-2.5Kg for the rabbits. The male and female were half each, with 10 young and 6 large rats and 6 domestic rabbits. Room temperature was 18-20 ° C and relative humidity was 62% -70%.

Hypoglycemic Effects of Alloxic Hyperglycemic Models in Large Rats

Sixty large rats were randomly assigned to six tanks, ie, physiological saline bases, hyperglycemic model saline bases of the oxalic acid type, large amounts of model + capsules, weight, and small doses (1.0 g / Kg, 0.5 g / Kg, 0.25 g /). Kg, same as below), Model + phenethyldiguanidose (90mg / Kg, Jiangsu Forbidden Pharmaceutical Co., Ltd., China) ), 950811, the same below). Each group had 10 animals, and the males each accounted for half.

The animals were fasted for 12 hours, and then blood was cut by measuring their blood glucose levels. (Glucose oxidase ( ) -Peroxide Catalyst Method ( Subsequently, 40 mg / Kg of alloxane (manufactured by Sigma Company) was injected into the subcutaneous vein of other animals in the basal saline and other animals at the same time. The solution was injected above to prevent shock from hypoglycemia. After 48 hours, blood was taken on an empty stomach, and blood glucose was measured to confirm that the blood glucose was already high. After 72 hours of making the model, he started feeding the medicine, and then fed 2ml / 100g once daily for 10 consecutive days. Four hours after the last dose of medicine, blood was measured after cutting the tail on an empty stomach, and blood glucose was measured. The results are shown in Table 8.

Table 8

Effect of Capsule A on Blood Glucose in Large Rats

▲▲ P <0.01 compared to before making the model, compared to high blood sugar

* P <0.05, ** P <0.01

The above results indicate that the blood sugar level of the high glucose model animals is much higher than before the model (P <0.01). Model + phenethylyl guanide ( After injecting the drug into the crude animals, blood glucose levels were significantly lower than those in the model baseline, and the statistical significance was very clear (P <0.01). The large amount and weight of the capsule a, the blood glucose level was significantly lower than the model reference tank (P <0.01), and even a small dose (P <0.05). The results confirm that capsule a acts to significantly reduce blood sugar levels in large rats of the high blood glucose model of alloxan type.

2. Hypoglycemic Model of Subsignal-Lmon Type Hyperglycemia in Large Rats

Sixty large rats are randomly divided into ten groups in each group, including normal physiological saline reference group, subsignal model model group, model + phenethyldiguanide group, model + capsule large amount, weight, and small dose group. The animals were fasted for 12 hours before the experiment, cut their tails, collected blood, and measured normal blood glucose levels. Then, a model was prepared by injecting 1.0 mg / Kg of subsignal hormone into the skin of each animal except the normal saline reference tank. After 1 hour, blood is taken on an empty stomach, and blood glucose is measured to confirm that the blood sugar is already high, and then the medicine is injected once. After injecting medicine, cut blood pressure on 0.5%, 1.0 hour and 2.0 hours by cutting tail on an empty stomach. The results are shown in Table 9.

Table 9

Effect of Capsule a on Hyperglycemia of Hyperglycemic Model in Rats

Compared to before making the model ▲▲ P <0.01

* P <0.05, ** P <0.01

The results indicate that blood glucose levels in hyperglycemic model animals are much higher than levels prior to modeling (P <0.01). The blood glucose level was significantly lower than that of the model control group after injecting the drug into the model + phenethyldiguanide group (P <0.01). In the large dose and weight doses of capsule a, the blood glucose level was remarkably reduced compared to the model reference dose, and the medium dose was not obviously lowered in blood within 0.5 hours after injection of the drug (P> 0.05). However, within 1.0 and 2.0 hours after infusion of the drug, there was a pronounced glucose effect (P <0.05 or P <0.01), indicating that capsule a significantly reduced the blood glucose levels of the hypersignal hyperglycemic model in large rats.

3. Effects on Normal Glucose Blood Sugar

Fifty rats were randomly divided into five groups, namely normal physiological saline standard group and right gangangdan group ( ) (1.0mg / Kg, provided by Tianjin Pharmaceutical Research and Development Company of China, with a combined cirrhosis number 961075), divided into a large amount, weight and small dose of capsule a. Each group had 10 animals and half males. The group of animals injected with the drug is infused four days in a row, with a dose of 0.2ml / 10g once daily. Fasting for 12 hours before the last drug was injected, and 0.5 and 1.0 hours after the drug was injected, the tail was cut and blood was collected from an eye rim to measure blood glucose (results are shown in Table 10).

Table 10

Effect of Capsule A on Blood Glucose in Normal Rats

* P <0.05, ** P <0.01 compared to normal saline reference tank

The results showed that when the drug was infused for 4 consecutive days, the large dose of capsule a showed a significant decrease in blood glucose both 0.5 and 1.0 hours after the last drug was injected. P <0.01), but the weight, small dose tank shows that the blood glucose reduction effect is not significant (P> 0.05) within 1.0 hours after the last drug injection. The above experiments suggest that capsule a has a distinct auditory effect on normal pups.

4. Influence on the domestic equivalence of rabbits

36 rabbits were divided into six groups, including normal saline reference bath, saline glucose bath, phenethyldiguanide + glucose bath, and large amount, weight, small amount + glucose bath of capsule a. Each group of animals was fasted for 14 hours before the experiment, and blood was drawn on an empty stomach. Next, after 1 hour of injection of 10 ml / Kg of medicine, 4 ml / Kg of 50% glucose solution was injected into the abdominal cavity and bleeding from the ear artery, and blood glucose levels of 0.5, 1.0, and 3.0 hours were measured after glucose injection. . Next, draw the equivalence curve of the rabbit and draw an area meter ( ), The area under the blood glucose curve was calculated, and the t-test was performed. The results are shown in Table 11.

Table 11

Effect of Capsule a on the Equivalence of Rabbits (n)

** P <0.01 compared with brine + glucose

Experimental results on the effect of capsule a on the equivalent weight of rabbits are as follows. All medication-injected baths can significantly lower the equivalent weight curve. Blood glucose at different times is all lower than in saline glucose baths. The area under the equivalent weight curve of the large-weight, weight-dose tanks of phenethyldiguanide and capsule a has a significant statistical significance (P <0.01) compared to the saline glucose bath. The area under the blood glucose curve of the small-dose tanks tends to be smaller, but the statistical significance is not significant (P> 0.05). This suggests that capsule a significantly enhances the equivalent weight of rabbits.

Capsule A has a marked decrease in blood glucose levels in normal pups, and an alloxic and adrenergic hyperglycemic model also has a marked decrease in blood glucose levels. Significantly improve.

Experimental Example 4: Effect of Capsule a on Serum Insulin Levels in Large Alloxan Diabetic Rats

Experimental Animals: Large rats of SD breed, weight 150-200g, provided by Xi'an Medical University Experimental Animal Center.

Medical device: one touch (ONE TOUCH) type of blood sugar ) (Johnson Corporation,

FJ-2008r line immune counter (FJ-2008r )(West Coast( 262 Factory Products

Medications and reagents: Capsule a, 1 g of powder corresponds to approximately 19 g of herbal medicine. To prepare a suspension of the concentration required for the experiment with distilled water. Alloxan (Alloxan, Sigma Company)

Phenyldiguanide (Ration No.950811, Jiangsu Saltan Pharmaceutical Factory), Insulin release measurement reagent ( (Beijing North Biotechnology Research Institute).

100 large rats are randomly divided into 2 groups, physiological saline reference group (n = 10) and alloxan type diabetic model (n = 90). After 12 hours of fasting, the animals are cut and blood is collected to measure normal blood sugar and insulin levels. Next, the model animal is injected intraperitoneally with 0.4% / 100g of 4% alloxic saline solution once a day. The reference tank is injected with the same amount of saline solution. Blood is taken on an empty stomach 5 days after injection to measure normal blood glucose and insulin levels. In the model group, animals with 17-27.7 mol / L of blood sugar were selected and divided into physiological saline reference group, model reference group, and model + phenethyldiguanide (90mg / Kg) group. Do not exceed mmol / L. Each crude animal is infused with a standard 20 mg / kg dose once daily for 20 consecutive days or with saline solution to measure blood glucose and insulin levels on an empty stomach on the 10th and 20th days. As a result, the group of animals injected with the drug showed a significant decrease in blood glucose levels on days 10 and 20, and the large, weight, and small doses of capsule a showed high serum insulin levels on day 20 (P < 0.01). This confirms that capsule a significantly reduces blood sugar and promotes insulin secretion in large alloxia-type diabetic rats. Same as 12).

Table 12

Effect of Capsule A on Blood Glucose and Serum Insulin Levels

Compared with before model: ▲▲ <0.01, * P <0.05, ** P <0.01 compared with high sugar model reference group.

The above pharmacological studies indicate that the capsule a of the present invention significantly reduces the blood glucose of the alloxic type hyperglycemic group, promotes the secretion of insulin, and has a certain recovery function in the damage of alloxan spleen β.

Application Example 109 Clinical Observations of Diabetes Treatment with Capsule a.

In February-October 1997, the observational analysis of the clinical treatment effect (capacity was 45 days) for 109 diabetic patients by capsule a was as follows.

一. Test case standard

1. Payment Case Standards:

All patients who meet the 1980 WHO Diabetes Classification Standards are in this case.

2. Exclusions Case Standards (including non-adaptive and excluded standards)

(1) Patients should have a fasting blood glucose level lower than 7.8 mmol / L after food deduction or increased activity even if the blood sugar level is higher than normal before taking the herbal medicine preparation of the present invention. Or, blood sugar after 2 hours of meal should be lower than 11.1 mmol / L (200 mg / dL).

(2) Patients under the age of 18 or 65 years of age or pregnant or lactating women and patients with hypersensitivity to this drug.

(3) Patients who do not cooperate (ie patients who do not cooperate with food restrictions or do not take medications in accordance with regulations, which affect the effectiveness of the medication)

(4) Patients with psychological complications or other serious recurrent illnesses that cause serious complications in the heart, liver or kidneys.

(5) diabetic ketoosis or ketoacids in about one month ( Poisoning or infected.

(6) Patients with discontinued treatment prior to the specified observations and whose treatment cannot be determined or whose data are incomplete.

二. Observation

1. Safety inspection

(1) General physical examination.

(2) Blood sugar, urine glucose test and blood, urine fluid regular test.

(3) Some patients undergo heart, kidney, and liver function tests.

2. Therapeutic Effect Test

(1) Inquire about medical history in detail to understand factors affecting blood glucose change such as food status, activity level, psychological status, diabetes knowledge, emergency status, and observe major clinical symptoms and changes in constitutional characteristics.

(2) Fasting and measuring blood glucose for 2 hours after meals are measured once every 7-10 days after administration of medicine.

(3) Measure the amount of urine glucose for 24 hours once every 7-10 days after administering the medicine.

(4) glycated hemolytic protein ( )inspection

(5) Plasma insulin cpeptide quantitative detection.

(6) spleen hyperglycemia test.

(7) splenocyte antibody, insulin receptor , Antibodies ( Check).

The above items (1) and (2) must be carried out and other items should be selected according to the condition of the condition and medical conditions. After taking capsule a, fasting blood glucose and urine glucose are checked every 10-15 days to observe the unit treatment schedule (45 days) and before treatment.

Starting from the date of observation, patients are required to have reasonable food restrictions. Stocks are generally set as follows according to various labor intensity and body type.

Recreational or overweight patients are limited to 200-300g daily.

General workers 300-350g daily.

For heavy workers, 400-500 grams daily, and the necessary calories other than stocks are supplemented by corrosion depending on circumstances.

三. Clinical observation

1. General data

a. Gender age: 65 male patients, 44 female patients. Of these, 4 patients were Type I (insulin dependent) and 105 patients were Type II (non-insulin dependent).

As shown in Table 13, 87 cases occurred between 46 and 65 years of age, accounting for 79.81% (87/109) of this section, mainly patients with type II diabetes.

Table 13

Gender age distribution table

b. Occupation: This section contains 76 executives, 21 workers, 8 housewives, 3 farmers, and 1 other person, with a high incidence of executives, accounting for 69.72% (76/109) of this article. Most executives may have a high incidence because of their relatively low physical activity and relatively good living and food conditions.

c. Onset: Less than 1 year to more than 20 years (see Table 14).

Table 14

Onset Process and Gender Distribution

2. Treatment and Observation

a. Medication Administration Method: Capsule a. It is mainly used to treat type II diabetes and can be administered experimentally to patients with type I diabetes without other serious complications.

How to take: Take 4 capsules 3 times a day, three times daily for 45 consecutive days.

b. Treatment schedule: 45 days as a unit treatment schedule, blood glucose and urine glucose are repeatedly tested on an empty stomach and after meals every 10-15 days after the administration of medicine. 13 of them measure spleen function and compare before and after treatment.

3. Criteria for Determination of Therapeutic Effect

a. Significant effect: After treatment, the symptoms disappear essentially, the fasting blood glucose level is lower than 7.2 mmol / L, the blood glucose level after 2 hours is lower than 8.3 mmol / L, and the urine glucose level is lower than 10.0 g after 24 hours. Alternatively, blood glucose and 24-hour urine glucose should be reduced by at least 30% compared to pretreatment.

b. Efficacy: Symptoms should be remarkably improved after treatment, fasting blood glucose level lower than 8.3 mmol / L, blood glucose level less than 10.0 mmol / L after 2 hours of meal, and urine glucose level after 24 hours after meal should be lower than 25.0 g. Alternatively, blood glucose and 24-hour urine glucose should be reduced by at least 30% compared to pretreatment.

c. Invalid: There is no marked improvement in symptoms after treatment and the reduction in blood sugar and urine glucose does not reach the above standard.

4. Treatment Results and Conclusion

a. Blood Glucose: There were 4 invalids in this group and the mean 105 blood glucose reduction was 5.94 ± 2.5 mmol / L. Glucose changes before and after treatment are shown in Table 15 below.

Table 15

Scorecard level of treatment effect

b. Disease symptoms: Symptoms improved or disappeared after treatment (Table 16).

c. Side effects: About 8% of patients had symptoms such as swelling of the stomach and loss of appetite while taking the medicine, and diarrhea or constipation. After taking the medication with or after meals, the symptoms were alleviated and treatment continued.

Table 16

Symptom list before and after treatment

CONCLUSION: The basic clinical observations of 109 diabetic patients (4 types I and 105 types II) of this article explain the following phenomena. This drug has a clear auditorium effect, total efficiency is 96.33% (significant efficiency 63.33%, effective rate 33.03%), and only 4 cases (3 cases of type I and 1 case of type II) are only 3.67%. Five of the patients had been treated with insulin and gradually reduced their insulin dose after taking capsule a, so that three patients can still maintain abnormal levels even though the three patients have already stopped taking insulin.

Capsule A mainly treats type II diabetes and has a certain therapeutic effect on type I. In addition to lowering blood sugar effectively, the drug has a relatively good effect on prevention and improvement of clinical complications, making it one of the most promising drugs among antidiabetic drugs.

Application example 2:

angularity( ), 63 years old, has been symptomatic of unpleasant, frequent urination, excessive drinking, thinness, and sweet food. The blood glucose level before treatment was 12.1 mmol / L and urine glucose was ++. He was diagnosed with type II diabetes. After taking various medications, the treatment effect was not ideal, the symptoms were repeated several times, the symptoms were clear, the legs were low and painful, and the daily meal (stock) was 250g. Example 4 of the present invention (filled rain drops) was taken three times daily, 1.6 g each time, and the treatment was observed. After 30 days of administration of the drug, the blood sugar was lowered to 8.2 mmol / L. The current general situation is good, sometimes the legs are tingling and painful for a short time, blood glucose was 7.2mmol / L at 2 hours after eating, and urine glucose was negative. It is still under the treatment of treatment, and according to the criteria for judging the effectiveness of treatment, this is one of the examples.

Application example 3:

Mother, 53 years old, thirsty since July 1997. He had thirst, overeating, heavy drinking, and urine. Body blood pressure was checked at 15/40 kpa and cardiopulmonary was negative. Diabetes mellitus was diagnosed as type I diabetes through tests such as glucose tolerance and insulin release. Blood glucose was less than 17.5 mmol / L and urine glucose was ++++ before treatment. Example 5 of the present invention was used as a filler (woorim drug) b was taken three times daily, 1.6g each time. 30 days after the administration of the medicine, the blood sugar went down to 4.4 mol / L, the urine sugar was negative, and the amount of food was more than 500g every day and fruit can be eaten. According to the criteria for judging the effect of treatment, this belongs to the examples of remarkable effects.

Application example 4:

Mother and daughter , 44 years old, over 4 years ago, was overwhelmed and skinny, and had high blood sugar. He was diagnosed with type II diabetes through further equivalent-resistant insulin release experiments. After taking the auditory drug D860 and phenethyldiguanide, the blood glucose restriction was not good, and Example 6 of the present invention was restored. Fasting blood glucose was 14.7 mmol / L and urine glucose was ++ before treatment. Example 6 of the present invention after taking 46 tablets three times a day for one tablet each time fasting blood sugar was lowered to 5.8 mmol / L /. The general situation is good now, the symptoms of overeating, skinny, languid, etc. disappeared in clinical trials, food is not strictly limited, and even a small amount of fruit, blood sugar is limited to a level satisfactorily satisfied. It is still under treatment, and the criteria for treatment effect are considered to be remarkable effects.

Application example 5:

Mother, 65 years old, with heavy drinking, polyuria, and nausea since April 1997, weight loss gradually decreased by 14 kg in three weeks. Blood glucose was 15.7 mmol / L, urine glucose was ++++, and blood pressure was 18/12 kpa. ) Is (-), weight 68 Kg, blood ) Has been diagnosed as type II diabetes. It was treated by taking the capsule b of Example 2 of the present invention and recovered four times each day three times a day. After taking 10 days, urine glucose became negative, and the weight increased by 2 kg to 70 kg. After 30 days of treatment, the 'three more and one less' symptoms disappeared completely, but the general situation is good. The food is not already limited and can be eaten with fruits and puffs. Blood sugar is 5-7mmol / L, urine sugar is negative and the dose is controlled by itself. According to the criteria for judging the effect of treatment, this belongs to the examples of remarkable effects.

Application Example 6:

Mother, 61 years old, in May 1991, physical examination revealed diabetes and was diagnosed with type Ⅱ diabetes. Blood glucose was 14.0 mmol / L, and urine glucose was +++. At the retest in March 1997, blood glucose levels were 14.2 mmol / L and 12.9 mmol / L, and urine glucose was +++. When the blood sugar was 13.9 mmol / L and the urine glucose was +++ on April 1, 1997, the capsule c of Example 3 of the present invention was taken. Each time, 4 tablets were taken 3 times a day. After one month, blood glucose was 6.8 mmol / L and urine glucose was negative. The food is normal without limitation, with 2-3 tablets daily and sometimes no medication. Blood glucose was measured about 20 days after stopping on Feb. 2, 1998, and was still 7.1 mmol / L. According to the criterion for treatment effect, this belongs to the example of remarkable effect.

Herbal medicines of the present invention was selected as a herbal medicine that is warm, consonant, bozy, ripe and full-bodied herbal medicine It is a drug. Oriental Medicine Formulated according to the theory. And stirs and cures diabetes, especially type II diabetes. According to clinical observations of more than 6,000 diabetic patients, the total efficacy rate is 96.33%. Generally speaking

1. The treatment schedule is 2 months, under normal circumstances, the patient begins to take 10 days to see the effect, and after 1 month, the blood sugar and urine sugar go down to the normal or normal level. Subsequent treatments gradually reduce the dose depending on the glucose situation.

2. After 2 months, about 80% of patients' insulin function is restored or improved to some extent.

3. The herbal herbal medicines of the present invention temporarily lower blood sugar and urine glucose as well as treat the source of the disease, thereby gradually recovering or improving insulin function. This drug is currently one drug that can not reach the same class of diabetic drugs at home and abroad.

As described above, according to the present invention, by providing the herbal medicines composed of the substance extracted from rhubarb, ginseng, gimo, dansam as an active ingredient, it is used in the treatment of diabetes, especially type Ⅱ diabetes, lowering blood sugar, urine glucose or You can see a therapeutic effect such as gradually restoring the function of insulin.

Claims (10)

Herbal herbal medicine for the treatment of diabetes, characterized in that the active material comprises an extract obtained by adding alcohol and / or water to the following raw materials or the following raw materials; Sulfur 600-900 wt. Ginseng 450-750 wt. Astragalus 800-1200 weight part Hyunsam 450-550 weight part 550-750 weight part yellow white 780-1420 weight part Creation 450-550 weight portion Salvia 550-750 weight portion Soy sauce 450-550 parts by weight phalanges 550-750 parts by weight. Herbal herbal medicine for the treatment of diabetes, characterized in that the active material comprises an extract obtained by adding alcohol and / or water to the following raw materials or the following raw materials; Sulfur 700-780 wt% Ginseng 570-630 wt% Astragalus 970-1070 weight part Hyunsam 475-525 weight part 630-700 weight part Yellowish white 1100-1250 weight part Creation 475-525 weight portion Salvia 630-700 weight portion Soy sauce 475-525 parts by weight phalanges 630-700 parts by weight. Herbal herbal medicine for the treatment of diabetes, characterized in that the active material comprises an extract obtained by adding alcohol and / or water to the following raw materials or the following raw materials; Sulfur 740 wt. Ginseng 600 wt. 1020 weight part of Astragalus 500 weight part 666 weight powder yellow white 1200 weight powder For 500 kg of creation salvia 666 weight 500 kg of rice flour 666 weight of phalanges. The method according to any one of claims 1 to 3, The herbal herbal medicines for the treatment of diabetes, characterized in that prepared in any dosage form prescribed by pharmacy. The method of claim 4, wherein Herbal medicines for the treatment of diabetes, characterized in that the capsule is a capsule. ① measuring and preparing the following herbal medicines with a scale; Sulfur 600-900 wt. Ginseng 450-750 wt. Astragalus 800-1200 weight part Hyunsam 450-550 weight part 550-750 weight part yellow white 780-1420 weight part Creation 450-550 weight portion Salvia 550-750 weight portion Soy sauce 450-550 wt. ② obtaining active ingredient I which is an extract obtained by adding alcohol and / or water to the powder of ginseng and heating it; ③ adding water or an acidic aqueous solution to the powder of the sulfur and yellow white powder, and then obtaining the active ingredient II which is a leaching solution obtained by cold sedimentation; ④ obtaining the active ingredient III which is an extract obtained by soaking the other seven herbs in water; ⑤ A method for preparing herbal medicines, which is an antidiabetic agent, comprising the step of mixing the active ingredients I, II and III evenly. The method of claim 6, The heating spin described in step ② is carried out three times, the heating spin solution is a method for producing a herbal medicine for the treatment of diabetes, characterized in that the aqueous ethyl alcohol solution. The method according to claim 6 or 7, The method of producing a herbal medicine for the treatment of diabetes, characterized in that the heating reflux of step ② is 55% -80% ethyl alcohol solution. The method according to claim 6 or 7, The method of producing a herbal medicine for the treatment of diabetes, characterized in that the heating reflux of step ② is 75% ethyl alcohol aqueous solution. The method according to any one of claims 6 to 8, Extracting with water in step ④ is extracted three times each 2 hours each time, the amount of the solvent to prepare a Chinese herbal medicines for the treatment of diabetes, characterized in that 10 times the amount.